Hence, it appears that a gene signature composed of the 6 top overexpressed genes in PR + SD samples, namely CHGA, FGF10, PTPRC, MIA, TRIM72 and SEC14L2 (Supplementary Fig. 2b), may predict benefit of patients to our combination therapy. The gene discussed is FGF10; the disease is Salla disease.